Showing 1–7 of 7 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, et al.
… were enrolled in a multicenter, parallel-group, randomized clinical trial in India. Patients were randomized to 26 weeks of bedaquiline, pretomanid, and daily linezolid, at 600 mg for 26 weeks (arm 1); 600 mg for 9 weeks followed by 300 mg for 17 weeks (arm 2); or 600 mg for 13 …
Naidoo K, Naidoo A, Abimiku AG, Tiemersma EW, Gebhard A, et al.
…ve of rifampicin (RIF) resistance (RR) status) from several clinical sites across South Africa, Nigeria and Ethiopia will be enrolled over 18-24 months and followed-up for approximately 6 months post-TB treatment completion. Participants will be enrolled into one of two cohorts b…
Alberto Matteelli, Sofia Lovatti, Benedetta Rossi, Luca Rossi
…evidence, two large-scale prospective randomized controlled trials were conducted: VQUIN (VQUIN MDR Australia New Zealand Clinical Trials Registry number, ACTRN12616000215426) and TB-CHAMP (TB-CHAMP ISRCTN Registry number, ISRCTN92634082). Both trials evaluated the efficacy of le…
Yao Qin, Yuanyuan Chen, Qingshan Cai
…s was a single-arm, prospective, monocentric, observational trial. From June 2020 to January 2023, 29 patients meeting the inclusion criteria were selected from Hangzhou Red Cross Hospital. These patients received a treatment regimen that included Dlm. Data were collected on pati…
Wang Q, Pang Y, Jing W, Liu Y, Wang N, et al.
… was the time to sputum culture conversion on solid medium. Clinical outcomes of patients were evaluated at the time of treatment completion. Of the 22 patients in the experimental group, 7 (31.8%) met the treatment criterion of "cure" and 1 (4.5%) "complete treatment," for a tot…
Patra J, Irving H, Maini P, Liang J, Patra A, et al.
…r approximately a third of pediatric MDR-TB cases globally. Clinical management is challenging; recommendations are based on limited evidence. We assessed the clinical outcomes for children and adolescents treated for XDR-and pre-XDR-TB. We performed a systematic review and meta-…
Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, et al.
…as associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 201…